| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 5,935,900 | 5,459,520 | 5,138,700 | 4,957,840 | 4,585,060 |
| Sales Growth | +8.73% | +6.24% | +3.65% | +8.13% | +47.55% |
| Net Income | 782,300 | 614,640 | 378,240 | 107,030 | 243,890 |
| Net Income Growth | +27.28% | +62.50% | +253.40% | -56.12% | -38.63% |
Steris Corp (STE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
STERIS plc, develops, manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. On Nov 2, 2015, STERIS completed the acquisition of Synergy Health plc following which it was re-registered under the name ' STERIS plc. Currently, STERIS serves healthcare, pharmaceutical, research, industrial and governmental customers across the globe. The majority of STERIS' revenues is derived from the healthcare and pharmaceutical industries. STERIS provides its products and services in more than 60 countries. The company's key areas of strategic focus include developing its customer base in Europe, the Middle East and the Asia Pacific region.
Fiscal Year End Date: 03/31